The SocietyVote now in the 2021 senior leadership electionsLearn more and vote
Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension contribute markedly to the global burden of chronic respiratory disease. Despite this, the burden of pulmonary vascular diseases remains underestimated, and the significance of pulmonary vascular disease merits greater attention from the medical community.
This year’s ERS International Congress programme includes a dedicated track with a variety of sessions and activities for health professionals involved in the treatment and management of pulmonary vascular diseases, and for researchers who are interested in this disease area.
Q: The congress theme is digital health. Why is this area important for pulmonary vascular disease specialists?
A: We all see the potential interest of digital health in pulmonary vascular diseases with the slow move to virtual consultation, accelerated by the COVID-19 pandemic; remote transmural multidisciplinary team meeting, to discuss difficult cases with rare forms of pulmonary hypertension; at-distance monitoring of vital parameters, which is of interest in patients with severe hemodynamic compromise; and the use of artificial intelligence to facilitate the interpretation of CT scans, and to better differentiate PAH from PH due to left heart disease.
Q: Is there a specific session in this track that should not be missed?
A: The state-of-the-art session on pulmonary vascular diseases (09:30–11:00 CEST on 7 September).
Q: What do you think will be the popular topics in the pulmonary vascular disease field at this year’s Congress, and what will be a particular highlight for you?
A: For me, the most important topics to look forward to are:
Q: What does congress offer to early career professionals who specialise in pulmonary vascular diseases?
A: This year’s virtual Congress allows the early career professional to update themselves with the latest advances in pulmonary vascular disease. Personally, I am looking forward to the ‘pro con’ debate (12:20–13:00 CEST on 6 September), given the proposed change in haemodynamic definition of pulmonary hypertension.
Also, there are many fantastic sessions offered pertaining to the management of our pulmonary embolism patients in challenging clinical situations. As an early career professional, do engage with each session by asking questions and find the time to network with the Assembly 13 members.